Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Clinical trial NCT05035745 · RECRUITING

Trial details

NCT number: NCT05035745
Sponsor: National University Hospital, Singapore
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Refractory Solid Tumors Advanced Triple Negative Breast Cancers Metastatic Triple Negative Breast Cancers

Start date: 2021-03-01
Primary completion: 2027-11-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.